These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23742914)

  • 1. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma.
    Sitia G; Iannacone M; Guidotti LG
    J Hepatol; 2013 Nov; 59(5):1135-8. PubMed ID: 23742914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.
    Sitia G; Aiolfi R; Di Lucia P; Mainetti M; Fiocchi A; Mingozzi F; Esposito A; Ruggeri ZM; Chisari FV; Iannacone M; Guidotti LG
    Proc Natl Acad Sci U S A; 2012 Aug; 109(32):E2165-72. PubMed ID: 22753481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelets promote liver immunopathology contributing to hepatitis B virus-mediated hepatocarcinogenesis.
    Sitia G
    Semin Oncol; 2014 Jun; 41(3):402-5. PubMed ID: 25023356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic hepatitis B: role of anti-platelet therapy in inflammation control.
    Aiolfi R; Sitia G
    Cell Mol Immunol; 2015 May; 12(3):264-8. PubMed ID: 25578311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma: could antiplatelet drugs be used to prevent HBV-associated hepatocellular carcinoma?
    Greenhill C
    Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):425. PubMed ID: 22801727
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
    Liaw YF
    Semin Liver Dis; 2005; 25 Suppl 1():40-7. PubMed ID: 16103980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
    Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type II ground-glass hepatocytes as a marker of hepatocellular carcinoma in chronic hepatitis B.
    Mathai AM; Alexander J; Kuo FY; Torbenson M; Swanson PE; Yeh MM
    Hum Pathol; 2013 Aug; 44(8):1665-71. PubMed ID: 23574780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of intrahepatic lymphocyte subsets in a transgenic mouse model of immune-mediated hepatocarcinogenesis.
    Nakamoto Y; Kaneko S
    J Exp Clin Cancer Res; 2006 Mar; 25(1):55-7. PubMed ID: 16761618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG; Mohammed R; Yuen MF; Kao JH
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Triolo M; Della Corte C; Colombo M
    Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct effects of hepatitis B virus-encoded proteins and chronic infection in liver cancer development.
    Ringelhan M; Heikenwalder M; Protzer U
    Dig Dis; 2013; 31(1):138-51. PubMed ID: 23797136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery.
    Huang YH; Fang CC; Tsuneyama K; Chou HY; Pan WY; Shih YM; Wu PY; Chen Y; Leung PS; Gershwin ME; Tao MH
    Int J Oncol; 2011 Dec; 39(6):1511-9. PubMed ID: 21805030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
    Abu-Amara M; Feld JJ
    Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma and hepatitis B virus.
    Chan HL; Sung JJ
    Semin Liver Dis; 2006 May; 26(2):153-61. PubMed ID: 16673293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection.
    Lee PC; Yeh CM; Hu YW; Chen CC; Liu CJ; Su CW; Huo TI; Huang YH; Chao Y; Chen TJ; Lin HC; Wu JC
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):874-883. PubMed ID: 27541812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common clinicopathological features of the patients with chronic hepatitis B virus infection who developed hepatocellular carcinoma after seroconversion to anti-HBs--a consideration of the pathogenesis of HBV-induced hepatocellular carcinoma and a strategy to inhibit it.
    Tsuboi Y; Ohkoshi S; Yano M; Suzuki K; Tsubata SS; Ishihara K; Ichida T; Sugitani S; Shibazaki K; Aoyagi Y
    Hepatogastroenterology; 2006; 53(67):110-4. PubMed ID: 16506387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B.
    Zhang Z; Zhang JY; Wherry EJ; Jin B; Xu B; Zou ZS; Zhang SY; Li BS; Wang HF; Wu H; Lau GK; Fu YX; Wang FS
    Gastroenterology; 2008 Jun; 134(7):1938-49, 1949.e1-3. PubMed ID: 18455515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
    Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
    J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Cho HJ; Cheong JY
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.